CN114158734A - Composition for preventing or improving jaundice and application thereof - Google Patents
Composition for preventing or improving jaundice and application thereof Download PDFInfo
- Publication number
- CN114158734A CN114158734A CN202111436671.9A CN202111436671A CN114158734A CN 114158734 A CN114158734 A CN 114158734A CN 202111436671 A CN202111436671 A CN 202111436671A CN 114158734 A CN114158734 A CN 114158734A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- parts
- composition
- polysialic acid
- selenium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 206010023126 Jaundice Diseases 0.000 title claims abstract description 24
- 229920001661 Chitosan Polymers 0.000 claims abstract description 63
- 239000002253 acid Substances 0.000 claims abstract description 50
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000002105 nanoparticle Substances 0.000 claims abstract description 29
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 26
- 239000011669 selenium Substances 0.000 claims abstract description 26
- 239000006041 probiotic Substances 0.000 claims abstract description 23
- 235000018291 probiotics Nutrition 0.000 claims abstract description 23
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims abstract description 22
- 229950002441 glucurolactone Drugs 0.000 claims abstract description 22
- 230000000529 probiotic effect Effects 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims description 43
- 235000013350 formula milk Nutrition 0.000 claims description 28
- 235000013336 milk Nutrition 0.000 claims description 18
- 239000008267 milk Substances 0.000 claims description 18
- 210000004080 milk Anatomy 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 108010046377 Whey Proteins Proteins 0.000 claims description 7
- 102000007544 Whey Proteins Human genes 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000011707 mineral Substances 0.000 claims description 7
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 7
- 239000008158 vegetable oil Substances 0.000 claims description 7
- 239000011782 vitamin Substances 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims description 7
- 235000013343 vitamin Nutrition 0.000 claims description 7
- 235000021119 whey protein Nutrition 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 abstract description 42
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 11
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- UNKYOXKQMHLGPW-UHFFFAOYSA-N Urobilin IXalpha Natural products CCC1=C(C)C(=O)NC1CC2=NC(=Cc3[nH]c(CC4NC(=O)C(=C4C)CC)c(C)c3CCC(=O)O)C(=C2C)CCC(=O)O UNKYOXKQMHLGPW-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- KDCCOOGTVSRCHX-UHFFFAOYSA-N urobilin Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(C=C2C(=C(C)C(CC3C(=C(CC)C(=O)N3)C)=N2)CCC(O)=O)N1 KDCCOOGTVSRCHX-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 238000007580 dry-mixing Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 208000021130 Bilirubin encephalopathy Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000010235 enterohepatic circulation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000009775 high-speed stirring Methods 0.000 description 2
- 208000036796 hyperbilirubinemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000006663 kernicterus Diseases 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- JBDOSUUXMYMWQH-UHFFFAOYSA-N 1-naphthyl isothiocyanate Chemical compound C1=CC=C2C(N=C=S)=CC=CC2=C1 JBDOSUUXMYMWQH-UHFFFAOYSA-N 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- BPYKTIZUTYGOLE-UHFFFAOYSA-N billirubin-IXalpha Natural products N1C(=O)C(C)=C(C=C)C1=CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(C=C3C(=C(C=C)C(=O)N3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a composition for preventing or improving jaundice and application thereof. The composition comprises the following components in parts by mass: 100 parts of glucoaldonolactone, 100 parts of chitosan, 500 parts of selenium, 0.09-0.5 part of probiotic and 1.7-100 parts of probiotic; the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of the chitosan to the polysialic acid is (0.1-10): 1. According to the invention, the glucuronolactone and the chitosan are added into the composition and the proportion of the glucuronolactone and the chitosan is optimized, so that the glucuronolactone and the chitosan are synergistic in the aspect of promoting the metabolism of bilirubin of a newborn, and therefore, the jaundice is effectively prevented and improved.
Description
Technical Field
The invention relates to the field of food and medicine, in particular to a composition for preventing or improving jaundice and application thereof.
Background
Hyperbilirubinemia in newborns is one of the most common diseases in the neonatal period, with more than about half of newborns presenting varying degrees of jaundice. In severe cases, bilirubin encephalopathy can be caused, serious central nervous system lesions can be caused, the life and health of children patients can be threatened, and the fatality rate is high. 50-70% of neonates with bilirubin encephalopathy die in the acute stage, and about 75-90% of survivors leave serious neurological sequelae such as hearing impairment, abnormal vision, slow intellectual development and other neurobehavioral abnormalities. Therefore, the early prediction and timely intervention of the occurrence of the hyperbilirubinemia and the sequelae thereof of the newborn are of great significance.
Disclosure of Invention
The present invention is based on the discovery and recognition by the inventors of the following facts and problems: the inventor creatively discovers that the composition containing glucuronolactone, selenium, chitosan and probiotics can promote the digestion and discharge of bilirubin, thereby effectively preventing and improving jaundice.
The present invention is directed to solving, at least to some extent, one of the technical problems in the related art. Therefore, the invention provides a composition for preventing or improving jaundice and application thereof, wherein glucuronolactone and chitosan are added into the composition, and the proportion of the glucuronolactone and the chitosan is optimized, so that the glucuronolactone and the chitosan are synergistic in the aspect of promoting the bilirubin metabolism of a newborn, and therefore, the jaundice is effectively prevented and improved.
In order to achieve the aim, the invention provides a composition which comprises the following components in parts by mass: 100 parts of glucoaldonolactone, 100 parts of chitosan, 500 parts of selenium, 0.09-0.5 part of probiotic and 1.7-100 parts of probiotic.
According to a particular embodiment of the invention, in the above composition, the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of chitosan to polysialic acid is (0.1-10):1, preferably 2: 1.
According to a specific embodiment of the present invention, in the above composition, the glycan-polysialic acid nanoparticle is prepared by a method comprising: dripping the polysialic acid solution into the chitosan solution under the condition of stirring, continuing stirring after dripping is finished to obtain a mixed solution, and freeze-drying to obtain the chitosan-polysialic acid nanoparticles;
according to an embodiment of the present invention, in the above composition, it is preferable that the freeze-drying temperature is (-10) - (-50) ° c;
according to the embodiment of the present invention, in the above composition, it is preferable that the stirring speed at the time of dropping and/or after dropping is 500-.
According to a specific embodiment of the present invention, in the above composition, the selenium is selected from at least one of organic selenium and/or inorganic selenium.
According to a particular embodiment of the invention, in the above composition, the probiotic is selected from at least one of bifidobacteria and/or lactobacillus rhamnosus.
The invention also provides application of the composition in preparing food or medicine for preventing or improving jaundice.
According to a particular embodiment of the invention, in the above application, the food product is a formula milk powder.
The invention also provides a formula milk powder, which comprises the composition for preventing and improving jaundice and at least one of milk powder, whey protein powder, vegetable oil, lactose, vitamins or minerals.
According to a particular embodiment of the invention, in the above formula, the milk powderThe formula milk powder comprises the following raw materials in parts by mass: 0.1-1 part of glucuronolactone, 0.1-5 parts of chitosan and 1X 10 parts of selenium-4-4×10-30.002-1 part of probiotics, 30-40 parts of milk powder, 20-30 parts of whey protein powder, 10-20 parts of vegetable oil, 5-20 parts of lactose and 1-5 parts of vitamins and/or minerals.
According to a specific embodiment of the present invention, in the above formula powder, the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of chitosan to polysialic acid is (0.1-10):1, and more preferably 2: 1.
According to a specific embodiment of the present invention, in the above formula powder, preferably, the selenium is selected from at least one of organic selenium and/or inorganic selenium.
According to a specific embodiment of the present invention, in the above formula milk powder, preferably, the probiotic bacteria are selected from at least one of bifidobacterium and/or lactobacillus rhamnosus.
The composition for preventing or improving jaundice and the application thereof have the following beneficial effects:
the composition of the invention is added with glucuronolactone and chitosan and the proportion of the glucuronolactone and the chitosan is optimized, so that the glucuronolactone and the chitosan are synergistic in the aspect of promoting the metabolism of bilirubin of the newborn, thereby effectively preventing and improving the jaundice of the newborn. The formula milk powder disclosed by the invention is rich in nutrition, simple in preparation process and applicable to large-scale production.
Detailed Description
The technical solutions of the present invention will be described in detail below in order to clearly understand the technical features, objects, and advantages of the present invention, but the present invention is not limited to the practical scope of the present invention.
The invention provides a composition, which comprises the following components in parts by mass: 100 parts of glucoaldonolactone, 100 parts of chitosan, 500 parts of selenium, 0.09-0.5 part of probiotic and 1.7-100 parts of probiotic.
In the composition, glucuronolactone is converted into glucuronic acid under the catalysis of enzyme, bilirubin is combined with the glucuronic acid to form combined bilirubin, the physicochemical property of the bilirubin is changed, and the combined bilirubin is changed from fat-soluble unconjugated bilirubin with very low polarity into water-soluble conjugate-glucuronic acid bilirubin with relatively high polarity; combining with bilirubin, discharging into intestine via liver and bile, removing glucuronic acid under the action of intestinal bacteria, and changing into urobilinogen; most of the urobilin is oxidized into urobilin which is discharged from the excrement, and the urobilin is called as fecal bilin; part of urobilinogen is absorbed by intestine and returned to liver, and most urobilin returned to liver is converted into combined bilirubin, and then discharged into intestine along with bile to form 'enterohepatic circulation of bilirubin'; the remaining small part of urobilinogen is discharged from the kidney through the systemic circulation. On the other hand, chitosan can absorb intestinal unconverted bilirubin, thereby excreting bilirubin out of the body, reducing small intestinal reabsorption of bilirubin, and promoting "enterohepatic circulation of bilirubin" formed from glucuronolactone. The glucuronolactone and the chitosan in the composition of the invention act synergistically to accelerate the metabolism of bilirubin, thereby achieving the effect of preventing and improving neonatal jaundice.
Further, in the composition of the present invention, selenium can regulate immunity and protect liver, and the lack of selenium can cause impaired liver function; the probiotic bacteria can promote the combined bilirubin to be converted into urobilinogen and urobilin, so that the bilirubin is excreted out of the body through the excrement.
The composition for preventing and improving jaundice and the application thereof have the following beneficial effects:
the composition of the invention is added with glucuronolactone and chitosan and the proportion of the glucuronolactone and the chitosan is optimized, so that the glucuronolactone and the chitosan are synergistic in the aspect of promoting the metabolism of bilirubin of the newborn, thereby effectively preventing and improving the jaundice of the newborn. The formula milk powder disclosed by the invention is rich in nutrition, simple in preparation process and applicable to large-scale production.
According to a particular embodiment of the invention, in the above composition, the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of chitosan to polysialic acid is (0.1-10):1, preferably 2: 1. The composition of the invention preferably selects the addition form of chitosan, and is added in the form of chitosan-polysialic acid nano-particles, so that the utilization rate of chitosan can be improved, and the metabolic efficiency of bilirubin can be further improved, wherein the nano-particles formed in a preferable proportion have smaller and uniform particle size.
According to an embodiment of the present invention, in the above composition, preferably, the chitosan of the present invention is deacetylated by 80% or more.
According to a specific embodiment of the present invention, in the above composition, the glycan-polysialic acid nanoparticle is prepared by a method comprising: dripping the polysialic acid solution into the chitosan solution under the condition of stirring, continuously stirring to obtain a mixed solution after dripping is finished, freeze-drying to obtain the chitosan-polysialic acid nano-particles,
according to an embodiment of the present invention, in the above composition, it is preferable that the freeze-drying temperature is (-10) - (-50) deg.C.
According to the embodiment of the present invention, in the above composition, it is preferable that the stirring speed at the time of dropping and/or after dropping is 500-.
According to an embodiment of the present invention, in the above composition, preferably, the glycan-polysialic acid nanoparticle is prepared by: respectively preparing a chitosan acetic acid solution and a polysialic acid sodium dihydrogen phosphate aqueous solution with certain mass concentration, slowly adding the polysialic acid solution into the chitosan solution under the high-speed stirring of 500 plus one 1000r/min according to the mass ratio of chitosan to polysialic acid of (1.5-3):1, stirring for 1-2h after dropwise adding to obtain a mixed solution, freeze-drying the mixed solution at the temperature of (-10) - (-50) DEG C, and removing the solvent to obtain the polysialic acid-chitosan nanoparticles.
According to a specific embodiment of the present invention, in the above composition, the selenium is selected from at least one of organic selenium and/or inorganic selenium.
According to a particular embodiment of the invention, in the above composition, the probiotic is selected from at least one of bifidobacteria and/or lactobacillus rhamnosus.
The invention also provides application of the composition in preparing food or medicine for preventing or improving jaundice. The composition can be used as an additive and added into food or medicines to play a role in preventing or improving jaundice.
According to a particular embodiment of the invention, in the above application, the food product is a formula milk powder.
The invention also provides a formula milk powder, which comprises the composition for preventing and improving jaundice and at least one of milk powder, whey protein powder, vegetable oil, lactose, vitamins or minerals.
According to a specific embodiment of the invention, in the formula milk powder, the formula milk powder comprises the following raw materials in parts by mass: 0.1-1 part of glucuronolactone, 0.1-5 parts of chitosan and 1X 10 parts of selenium-4-4×10-30.002-1 part of probiotics, 30-40 parts of milk powder, 20-30 parts of whey protein powder, 10-20 parts of vegetable oil, 5-20 parts of lactose and 1-5 parts of vitamins and/or minerals.
According to a specific embodiment of the present invention, in the above formula powder, the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of chitosan to polysialic acid is (0.1-10):1, and more preferably 2: 1.
According to a specific embodiment of the present invention, in the above formula powder, preferably, the selenium is selected from at least one of organic selenium and/or inorganic selenium.
According to a specific embodiment of the present invention, in the above formula milk powder, preferably, the probiotic bacteria are selected from at least one of bifidobacterium and/or lactobacillus rhamnosus; further preferably, the final viable count of the probiotics reaches 3.6 multiplied by 106-5.2×108cfu/g。
According to a specific embodiment of the present invention, in the above formula, the preparation method of the formula comprises the steps of:
preparing materials: adding the raw materials except the composition into a mixing tank according to a preset proportion, heating to 40-55 ℃, mixing, and circularly stirring for at least 20min until uniformly mixing;
homogenizing: homogenizing at 55-65 deg.C and 20-30 MPa;
and (3) sterilization: sterilizing the homogenized mixed solution at 85-92 deg.C for 20-25 s;
concentration: concentrating at 55-65 deg.C to 46-52%;
spray drying: spray drying the concentrated mixed material liquid under the conditions that the air inlet temperature of the material is 160-180 ℃ and the air exhaust temperature is 80-90 ℃ to obtain base material powder;
dry mixing: adding the composition of the invention into the base material powder, and dry-mixing for 15-30min in a screw mixer until the mixture is uniform;
packaging: and (5) filling nitrogen into the vacuum and packaging to obtain the final product.
The present invention will be described in detail with reference to examples.
Example 1
The embodiment provides a formula milk powder, and the preparation method comprises the following specific steps:
preparation of Chitosan-polysialic acid nanoparticles
Respectively preparing 1.0g/L of chitosan acetic acid solution and 1.0g/L of polysialic acid sodium dihydrogen phosphate aqueous solution, slowly adding the polysialic acid solution into the chitosan solution according to the volume ratio of 2:1 under high-speed stirring at 600r/min, stirring for 1h after dropwise adding to obtain a mixed solution, freeze-drying the mixed solution at-20 ℃, and removing the solvent to obtain polysialic acid-chitosan nanoparticles for later use.
Preparation of formula milk powder
Preparing materials: weighing 35 parts of milk powder, 25 parts of whey protein powder, 15 parts of vegetable oil, 10 parts of lactose and 2 parts of vitamins and minerals, adding into a mixing tank, heating to 50 ℃, mixing, and circularly stirring for 200min until uniformly mixing;
homogenizing: homogenizing at 60 deg.C and 20 MPa;
and (3) sterilization: sterilizing the homogenized mixed material liquid at 88 deg.C for 20 s;
concentration: concentrating at 60 deg.C to 50%;
spray drying: spray drying the concentrated mixed material liquid under the conditions that the air inlet temperature of the material is 170 ℃ and the air outlet temperature is 90 ℃ to obtain base material powder;
dry mixing: adding 0.2 part of glucuronolactone and 0.6 part of chitosan-polysialic acid nano-particles (chitosan and polysialic acid) into base material powderThe mass ratio of acid is 2:1), selenium is 5 multiplied by 10-4The composition which is composed of the components of the composition and 0.05 part of bifidobacteria probiotics is dry-mixed in a screw mixer for more than 15min until the mixture is uniform;
packaging: and packaging by filling nitrogen in vacuum to obtain the formula milk powder product.
Example 2
The same preparation method as in example 1 was repeated, except that the composition contained 0.2 parts of glucuronolactone, 0.3 parts of chitosan-polysialic acid nanoparticles (the mass ratio of chitosan to polysialic acid was 2:1), and 5X 10 parts of selenium-4Parts of the mixture and 0.05 part of bifidobacterium probiotics.
Example 3
The same preparation method as in example 1 was repeated, except that the composition contained 0.2 parts of glucuronolactone, 1.5 parts of chitosan-polysialic acid nanoparticles (the mass ratio of chitosan to polysialic acid was 2:1), and 5X 10 parts of selenium-4Parts of the mixture and 0.05 part of bifidobacterium probiotics.
Comparative example 1
The same preparation method as in example 1 was used except that chitosan was used in the composition in place of the chitosan-polysialic acid nanoparticles, and chitosan was used in an amount of 0.4 parts.
Comparative example 2
The preparation method was the same as that of example 1 except that polysialic acid was used in place of the chitosan-polysialic acid nanoparticles and 0.2 part of polysialic acid was used in the composition.
Comparative example 3
The same preparation method as in example 1 was conducted except that the composition had a chitosan-polysialic acid nanoparticle in which the mass ratio of chitosan to polysialic acid was 10:1 and the amount of chitosan-polysialic acid nanoparticles was 0.44 part.
Comparative example 4
The same preparation method as in example 1 was conducted except that the composition had a chitosan-polysialic acid nanoparticle in which the mass ratio of chitosan to polysialic acid was 1:10 and the amount of chitosan-polysialic acid nanoparticles was 4.4 parts.
Comparative example 5
The same preparation as in example 1 was carried out, except that the chitosan-polysialic acid nanoparticles were not included in the composition.
Control group
The same procedure as for the preparation of example 1 is followed, except that the dry blending step of example 1 is eliminated without the addition of the composition.
The formula milk powder obtained in the above examples and comparative examples is tested for jaundice prevention and improvement effects, and the test method and results are as follows:
1. test method
220 mice of 6-8 weeks old were randomly divided into 11 groups of 20 mice each, and divided into male and female halves, a blank group, a model group, a control group, examples 1-3, and comparative examples 1-5.
The control group, examples 1 to 3 and comparative examples 1 to 5 were each administered with corresponding milk powder to mice, and the model group and the blank group were not administered with milk powder as food. Feeding continuously for 10 days. 2h after administration on the eighth day, the milk powder group and the model group were each administered with 0.4% ANIT olive oil solution (100mg/kg), the blank group was administered with the same volume of olive oil, the material was taken after 48h, fasting was not performed for 12h before the material was taken, after the mice were sacrificed after cervical vertebrae were removed, 1 liver tissue of 1.0 × 0.8 × 0.3cm size was excised from the right leaf of the liver, fixed with 10% neutral formalin, dehydrated, embedded, sliced, and observed for histopathological changes by hematoxylin-eosin staining (HE staining). And taking another liver, preparing homogenate by using cold normal saline, and detecting the liver homogenate cholesterol (Tc), Triglyceride (TG) and Malondialdehyde (MDA) according to the kit instruction.
During the experiment, the mice of each group are fed with milk liquid (prepared from milk powder and warm water at a ratio of 6: 1) and replaced every 12h to ensure the freshness of the milk liquid, and the residual milk amount is measured and recorded when the milk liquid is replaced every time. In order to ensure the nutrition supply of the mice, the milk is given and the feed is given at the same time, and the milk feeding ratio is 7: 3.
2. Statistical processing method
The measured data are expressed by mean ± standard deviation, and data processing is performed by using an SPSS18.00 software package. If the data are normally distributed and the variance among the groups is uniform, the data are processed by one-way ANORVA, the results are expressed as mean + -standard deviation, and multiple comparisons are performed by LSD method. The difference is statistically significant when P is less than or equal to 0.05.
3. Test results
Table 1 shows the effect of different formula milk on the index of the hepatitis model liver of the mouse jaundice model.
TABLE 1
As can be seen from Table 1, the levels of Total Cholesterol (TC), Triglyceride (TG) and Malondialdehyde (MDA) in the liver of the model group were significantly increased (P < 0.01) compared to the blank group, indicating the success of icterohepatitis.
Compared with a model group and a control group, the TC/TG/MDA level (P is less than 0.05) of the liver can be obviously reduced in examples 1-3, wherein the addition amount of chitosan in the examples 1-3 is respectively 0.4 part, 0.2 part and 1 part, the ratio of chitosan: sialic acids were all 1: 2. The experimental data show that the larger the addition amount of chitosan, the more effective the jaundice improvement. Comparative example 1 only 0.4 part of chitosan was added and comparative example 2 only 0.2 part of sialic acid was added, and by comparing with example 1, addition of chitosan alone reduced the liver TC/TG/MDA level, but the effect was significantly lower than example 1, and addition of sialic acid alone had almost no effect, which was not substantially the same as comparative example. Comparative example 3 and comparative example 4 both added 0.4 parts of chitosan but at different ratios of chitosan to sialic acid, 10:1 and 0.1:1 respectively. It was found by the data that less sialic acid was added (as in comparative example 3) and the jaundice reducing effect was significantly weaker than in example 1. While comparative example 4 is slightly superior to example 1, indicating that too much polysialic acid added does not have much advantage in improving jaundice.
Claims (10)
1. The composition is characterized by comprising the following components in parts by mass: 100 parts of glucoaldonolactone, 100 parts of chitosan, 500 parts of selenium, 0.09-0.5 part of probiotic and 1.7-100 parts of probiotic.
2. The composition according to claim 1, wherein the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of chitosan to polysialic acid is (0.1-10):1, preferably 2: 1.
3. The composition of claim 2, wherein the glycan-polysialic acid nanoparticle is prepared by a method comprising: dripping the polysialic acid solution into the chitosan solution under the condition of stirring, continuing stirring after dripping is finished to obtain a mixed solution, and freeze-drying to obtain the chitosan-polysialic acid nanoparticles;
preferably, the freeze-drying temperature is (-10) - (-50) deg.C;
preferably, the stirring speed during and/or after the dropwise addition is 500-.
4. The composition of claim 1, wherein the selenium is selected from at least one of organic selenium and/or inorganic selenium.
5. The composition according to claim 1, characterized in that the probiotic bacteria are selected from at least one of bifidobacteria and/or lactobacillus rhamnosus.
6. Use of the composition of any one of claims 1-5 for the preparation of a food or pharmaceutical product for preventing or ameliorating jaundice.
7. Use according to claim 6, wherein the food product is a formula.
8. A milk formula comprising a composition according to any one of claims 1 to 5 and at least one of milk powder, whey protein powder, vegetable oil, lactose, vitamins or minerals.
9. The formula milk powder according to claim 8, characterized in that the formula milk powder comprises the following raw materials in parts by mass: 0.1-1 part of glucuronolactone, 0.1-5 parts of chitosan and 1X 10 parts of selenium-4-4×10-30.002-1 part of probiotics, 30-40 parts of milk powder, 20-30 parts of whey protein powder, 10-20 parts of vegetable oil, 5-20 parts of lactose and 1-5 parts of vitamins and/or minerals.
10. Formula powder according to claim 8, characterized in that the chitosan is added in the form of chitosan-polysialic acid nanoparticles, wherein the mass ratio of chitosan to polysialic acid is (0.1-10) to 1, further preferably 2: 1;
preferably, the selenium is selected from at least one of organic selenium and/or inorganic selenium;
preferably, the probiotic bacteria are selected from at least one of bifidobacteria and/or lactobacillus rhamnosus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111436671.9A CN114158734A (en) | 2021-11-29 | 2021-11-29 | Composition for preventing or improving jaundice and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111436671.9A CN114158734A (en) | 2021-11-29 | 2021-11-29 | Composition for preventing or improving jaundice and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114158734A true CN114158734A (en) | 2022-03-11 |
Family
ID=80481539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111436671.9A Pending CN114158734A (en) | 2021-11-29 | 2021-11-29 | Composition for preventing or improving jaundice and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114158734A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112569263A (en) * | 2020-12-30 | 2021-03-30 | 湖北强飞生物科技有限公司 | Composite probiotic freeze-dried powder |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363801A (en) * | 1981-02-09 | 1982-12-14 | The Texas A&M University System | Method for treating hyperbilirubinemia |
| JPH04117328A (en) * | 1990-09-05 | 1992-04-17 | Chugai Pharmaceut Co Ltd | Body lipid storage-reducing agent |
| CN101011367A (en) * | 2005-09-26 | 2007-08-08 | 刘凤鸣 | Slow release tablet of glucurolactone |
| US20120294904A1 (en) * | 2011-05-19 | 2012-11-22 | Syracuse University | Polysialic acid-based n-trimethyl chitosan gel nanoparticles for systemic drug delivery |
| CN108991534A (en) * | 2018-03-14 | 2018-12-14 | 山东梵和生物科技有限公司 | A kind of formula powder reducing icterus neonatorum |
| CN111686134A (en) * | 2020-05-15 | 2020-09-22 | 上海市第六人民医院东院 | Probiotic composition and preparation method and application thereof |
| CN112244096A (en) * | 2020-10-28 | 2021-01-22 | 江南大学 | Selenium-rich modified milk powder containing probiotics and preparation method thereof |
| CN112569263A (en) * | 2020-12-30 | 2021-03-30 | 湖北强飞生物科技有限公司 | Composite probiotic freeze-dried powder |
-
2021
- 2021-11-29 CN CN202111436671.9A patent/CN114158734A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363801A (en) * | 1981-02-09 | 1982-12-14 | The Texas A&M University System | Method for treating hyperbilirubinemia |
| JPH04117328A (en) * | 1990-09-05 | 1992-04-17 | Chugai Pharmaceut Co Ltd | Body lipid storage-reducing agent |
| CN101011367A (en) * | 2005-09-26 | 2007-08-08 | 刘凤鸣 | Slow release tablet of glucurolactone |
| US20120294904A1 (en) * | 2011-05-19 | 2012-11-22 | Syracuse University | Polysialic acid-based n-trimethyl chitosan gel nanoparticles for systemic drug delivery |
| CN108991534A (en) * | 2018-03-14 | 2018-12-14 | 山东梵和生物科技有限公司 | A kind of formula powder reducing icterus neonatorum |
| CN111686134A (en) * | 2020-05-15 | 2020-09-22 | 上海市第六人民医院东院 | Probiotic composition and preparation method and application thereof |
| CN112244096A (en) * | 2020-10-28 | 2021-01-22 | 江南大学 | Selenium-rich modified milk powder containing probiotics and preparation method thereof |
| CN112569263A (en) * | 2020-12-30 | 2021-03-30 | 湖北强飞生物科技有限公司 | Composite probiotic freeze-dried powder |
Non-Patent Citations (3)
| Title |
|---|
| 何猛雄: "壳聚糖对胆红素吸附性能的研究", 《海南师范大学学报(自然科学版)》 * |
| 庄思齐等: "《实用儿科医嘱手册》", 30 June 2017, 中国协和医科大学出版社 * |
| 李丹: "离子交联法制备聚唾液酸/壳聚糖纳米粒", 《现代化工》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112569263A (en) * | 2020-12-30 | 2021-03-30 | 湖北强飞生物科技有限公司 | Composite probiotic freeze-dried powder |
| CN112569263B (en) * | 2020-12-30 | 2023-05-02 | 湖北强飞生物科技有限公司 | Composite probiotics freeze-dried powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019184419A1 (en) | Use of fullerene compound, fullerene microcapsule powder and preparation method and application thereof | |
| CN104304935A (en) | Infant formula rice flour improved through biotechnology and preparation method thereof | |
| CN1919043A (en) | Chicken feed addictive | |
| CN105146260A (en) | Functional food facilitating recovery of gastric mucosal lesion | |
| CN108157616B (en) | Puffed compound feed capable of reducing morbidity of frogs and improving body color of frogs | |
| KR101139372B1 (en) | Method for preparing feed additive and feed additivethere from | |
| CN114158734A (en) | Composition for preventing or improving jaundice and application thereof | |
| JP3720496B2 (en) | Novel pectin and emulsion containing the same | |
| CN109329415A (en) | A kind of baby formula milk powder | |
| CN112655802A (en) | Calcium gel candy and preparation process thereof | |
| CN112167440A (en) | Piglet artificial milk product replacing breast milk and processing method thereof | |
| CN110074189A (en) | A kind of infant's diatery supplement and preparation method thereof adding human milk oligosaccharides | |
| CN109169927A (en) | Calcium-rich yak milk powder, preparation method thereof and fermented milk product | |
| CN104548098A (en) | Enteral nutrient and preparation method thereof | |
| CN109717483B (en) | Jellyfish peptide formula food with special medical application | |
| CN1718011A (en) | Method for preparing sour milk contg. micron ginseng and antler etc. with tonifying-kidney and eliminating fatigue functions | |
| WO2019241901A1 (en) | Liver–intestinal axis-based liver-protecting intestinal micro-ecological regulator and preparation method thereof | |
| CN110037189A (en) | Promote Farrowing and mitigates the preparation method of postpartum syndrome feed addictive | |
| CN116649420B (en) | Nutritional milk powder with effects of nourishing intelligence and promoting digestion and absorption, and its preparation method | |
| CN116491657B (en) | Calcium preparation containing vitamin D and preparation method thereof | |
| NL2029452B1 (en) | Complex pack of infant formula milk powder with prebiotic function and preparation method thereof | |
| CN108618134A (en) | A kind of healthy diet intervention product and its preparation method and application | |
| CN108783460A (en) | A kind of nutrient powder and preparation method thereof containing alpha-linolenic acid, lecithin, vitamin E, soluble dietary fiber element | |
| CN108432946A (en) | A kind of feed addictive and preparation method thereof of prevention animal diarrhea | |
| CN112514996B (en) | Combination or composition, dairy product and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220311 |